Patients with newly diagnosed atrial fibrillation (AF) benefit from early rhythm control therapy, according to results of the EAST-AFNET 4 trial. The European study, presented at the ESC Virtual Congress and published in the NEJM, comprised 2,789 from 135 sites in 11 countries. Patients, with a median of 36 days since AF diagnosis, were randomised ...
Professor David Brieger: new evidence for early rhythm control in AF
By Mardi Chapman
9 Sep 2020